This program will explore key findings from a large global survey of health care providers and patients, uncovering unmet needs in patient care and key barriers to adoption of immunotherapies for relapsed/refractory multiple myeloma. Current treatment options, including practical considerations for the use of elranatamab, a BCMA-directed bispecific immunotherapy for certain adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, will also be discussed.

Speakers:

• Philippe Moreau, MD – University Hospital of Nantes, France
• Noopur Raje, MD – Massachusetts General Hospital, Center for Multiple Myeloma
• Rakesh Popat, MD, PhD, MRCP – University College Hospital